Maintenance with Rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis

Abstract

Granulomatosis with polyangiitis, microscopic polyangiitis and renal-limited anti-neutrophil cytoplasm antibody (ANCA) associated vasculitis are the main ANCA-associated vasculitidies (AAV). Multiple induction therapies for AAV exist and have proven successful in achieving disease remission. Azathioprine and methotrexate have been used to maintain remission of AAV, however, relapse rates and adverse effects with these medications remain high. Rituximab (RTX), a B cell depleting monoclonal antibody, was shown to be safe and effective in maintaining disease remission in AAV in early retrospective reviews. In 2014, the first randomized control trial to compare RTX and azathioprine in maintenance therapy of newly diagnosed AAV (MAINRITSAN trial), revealed that patients who received RTX after cyclophosphamide induction had higher rates of sustained remission, fewer adverse effects and, better overall survival rates as compared to azathioprine. MAINRITSAN 2 revealed that patients receiving tailored regimens of maintenance RTX received fewer infusions but did not have higher rates of relapse than patients who received fixed dose therapy. The RITAZAREM trial conveyed that patients who experienced AAV relapse after induction therapy that received induction and maintenance RTX were significantly less likely to develop a relapse at 24 months vs. patients who received maintenance therapy with azathioprine. Overall, these studies suggest that maintenance therapy with RTX represents an exceptional treatment option in patients with AAV in terms of safety and efficacy, resulting in lower relapse rates and less drug toxicity than conventional treatments. As a result, patients have fewer exposures to cytotoxic medications and thus, improved outcomes.

Keywords

Rituximab / ANCA vasculitis / maintenance therapy / B cell depletion / azathioprine / methotrexate

References

[1] Yates M.ANCA-associated vasculitis..Clin Med (Lond)2017;17:60-4 PMCID:PMC6297586

[2] Jennette JC.ANCA Glomerulonephritis and Vasculitis..Clin J Am Soc Nephrol2017;12:1680-91 PMCID:PMC5628710

[3] Fauci AS.Wegner’s Granulomatosis: studies in eighteen patients and a review of the literature..Medicine (Baltimore)1973;52:535-61

[4] Hassan RI.Rituximab in ANCA-associated vasculitis..Curr Rheumatol Rep2017;19:6

[5] de Groot K,Jayne D,Gregorini G.Pulse versus oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial..Ann Intern Med2009;150:670-80

[6] De Groot K,Bacon PA,Feighery C.Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis..Arthritis Rheum2005;52:2461-9

[7] Jayne DR,Rasmussen N,Ferrario F.Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis..J Am Soc Nephrol2007;18:2180-8

[8] Walsh M,Peh CA,Puéchal X.Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis..N Engl J Med2020;382:622-31 PMCID:PMC7325726

[9] Stone JH,Spiera R,Langford CA.Rituximab versus cyclophosphamide for ANCA-associated vasculitis..N Engl J Med2010;363:221-32 PMCID:PMC3137658

[10] Jones RB,Hauser T,Morgan MD.Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis..N Engl J Med2010;363:211-20

[11] Jayne D,Andrassy K,Tervaert JW.A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies..N Engl J Med2003;349:36-44

[12] Maritati F,Oliva E,Palmisano A.Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: a randomised trial..PLoS One2017;12:e0185880 PMCID:PMC5634660

[13] Pagnoux C,Hamidou MA,Ruivard M.Azathioprine or methotrexate maintenance for ANCA-associated vasculitis..N Engl J Med2008;359:2790-803

[14] Randall KL.Rituximab in autoimmune diseases..Aust Prescr2016;39:131-4 PMCID:PMC4993704

[15] Jennette JC.B cell-mediated pathogenesis of ANCA-mediated vasculitis..Semin Immunopathol2014;36:327-38 PMCID:PMC4084547

[16] Specks U,Mcdonald TJ.Response of Wegener’s granulomatosis to anti-CD20 chimeric monoclonal antibody therapy..Arthritis Rheum2001;44:2836-40

[17] Eriksson P.Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab..J Intern Med2005;257:540-8

[18] Bruhaye B,Pagnoux C,Guillevin L.Adjunction of Rituximab to steroids and immunosuppressants for refractory/relapsing Wegner’s granulomatosis: a study on 8 patients..Clin Exp Rheumatol2007;25:S23-7

[19] Jones RB,Chaudhry AN,Salama AD.A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis..Arthritis Rheum2009;60:2156-68

[20] Rhee EP,Niles JL.Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis..Clin J Am Soc Nephrol2010;5:1394-400 PMCID:PMC2924418

[21] Cartin-Ceba R,Keogh KA,Sánchez-Menéndez M.Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener’s): ten-year experience at a single center..Arthritis Rheum2012;64:3770-8

[22] Baudron-Roubaud C,Ruault-Meaux N,Zoulim A.Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis..J Rheumatol2012;39:125-30

[23] Guillevin L,Karras A,Aumaître O.Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis..N Engl J Med2014;371:1771-80

[24] Charles P,Perrodeau É,Faguer S.Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)..Ann Rheum Dis2018;77:1143-9

[25] Smith RM, Jayne D, Merkel P. A randomized, controlled trial of Rituximab versus Azathioprine after induction of remission with Rituximab for patients with ANCA-associated vasculitis and relapsing disease (RITAZAREM) [abstract]. Arthritis Rheumatol 2019;71. Available from: https://acrabstracts.org/abstract/a-randomized-controlled-trial-of-rituximab-versus-azathioprine-after-induction-of-remission-with-rituximab-for-patients-with-anca-associated-vasculitis-and-relapsing-disease/. [Last accessed on 28 Sep 2020]

[26] Henderson S,Pusey C,Salama A.Prolonged B cell depletion with Rituximab is effective in treating refractory pulmonary granulomatous inflammation in granulomatosis with polyangiitis (GPA)..Medicine(Baltimore)2014;93:e299 PMCID:PMC4602771

[27] Geetha D.ANCA-associated vasculitis: core curriculum 2020..Am J Kidney Dis2020;75:124-37

[28] Geetha D,Segelmark M,Morgan M.Rituximab for treatment of severe renal disease in ANCA associated vasculitis..J Nephrol2016;29:195-201

[29] Recillas-Gispert C,Flores-Suárez LF.Rituximab in the treatment of refractory scleritis in patients with granulomatosis with polyangiitis (Wegener’s)..Graefes Arch Clin Exp Ophthalmol2015;253:2279-84

[30] Suhler EB,Beardsley RM,Pasadhika S.Rituximab therapy for refractory orbital inflammation: results of a phase 1/2, dose-ranging, randomized clinical trial..JAMA Ophthalmol2014;132:572-8 PMCID:PMC4321949

[31] Sharma A,Wanchu A,Singh R.Successful treatment of hypertrophic pachymeningitis in refractory Wegener’s granulomatosis with rituximab..Clin Rheumatol2010;29:107-10

[32] Lally L,Huang WT.Effectiveness of rituximab for the otolaryngologic manifestations of granulomatosis with polyangiitis (Wegener’s)..Arthritis Care Res (Hoboken)2014;66:1403-9

[33] Cartin-Ceba R,Al-Qadi MO,Fervenza FC.Diffuse alveolar hemorrhage secondary to antineutrophil cytoplasmic antibody-associated vasculitis: predictors of respiratory failure and clinical outcomes..Arthritis Rheumatol2016;68:1467-76

[34] Tieu J,Basu N,D’Cruz D.Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines..Rheumatology (Oxford)2020;59:e24-32

[35] Reitblat T,Reitblat O.Rituximab-related late-onset neutropenia in patients with rheumatic diseases: successful re-challenge of the treatment..Am J Case Rep2015;16:211-4 PMCID:PMC4407679

[36] Berger JR,Lacey S,Lehane PB.Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event..J Neurovirol2018;24:323-31 PMCID:PMC5992248

[37] Segelmark L,Rathmann J.271. Severe infections in patients with anca-associated vasculitis treated with Rituximab..Rheumatology2019;58:kez062.045

[38] Kronbichler A,Gopaluni S,Alberici F.Trimethoprim-sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis..Ann Rheum Dis2018;77:1440-7

[39] Thiel J,Salzer U,Halmschlag K.Rituximab as induction therapy in eosinophilic granulomatosis with polyangiitis refractory to conventional immunosuppressive treatment: a 36-month follow-up analysis..J Allergy Clin Immunol Pract2017;5:1556-63

[40] van Dam LS,Bredewold EW,Bakker JA.Proteinase-3-anti-neutrophil cytoplasmic antibodies (PR3-ANCAs) predict relapses in ANCA-associated vasculitis patients after rituximab..Nephrol Dial Transplant2020;gfaa066